Valproic acid and sleep apnoea: A disproportionality signal from the WHO pharmacovigilance database

Bruno Revol; Ingrid Jullian-Desayes; Kelly Guichard; Jean-Arthur Micoulaud-Franchi; Renaud Tamisier; Pierre Philip; Marie Joyeux-Faure; Jean-Louis Pépin

doi:10.1111/resp.13771

Valproic acid and sleep apnoea: A disproportionality signal from the WHO pharmacovigilance database

Respirology. 2020 Mar;25(3):336-338. doi: 10.1111/resp.13771. Epub 2020 Jan 30.

Authors

Bruno Revol^{1

2

3}, Ingrid Jullian-Desayes^{1

2}, Kelly Guichard^{4

5

6}, Jean-Arthur Micoulaud-Franchi^{4

5

6}, Renaud Tamisier^{1

2}, Pierre Philip^{4

5

6}, Marie Joyeux-Faure^{1

2}, Jean-Louis Pépin^{1

2}

Affiliations

¹ HP2 Inserm U1042, Université Grenoble Alpes, Grenoble, France.
² Laboratoire EFCR, CHU Grenoble Alpes, Grenoble, France.
³ Centre Régional de Pharmacovigilance, CHU Grenoble Alpes, Grenoble, France.
⁴ Clinique du Sommeil, CHU de Bordeaux, Bordeaux, France.
⁵ SANPSY, Université de Bordeaux, Bordeaux, France.
⁶ SANPSY USR 3413, CNRS, Bordeaux, France.

PMID: 32000295
DOI: 10.1111/resp.13771

No abstract available

Keywords: pharmacovigilance; sleep apnoea syndromes; valproic acid.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Databases, Factual
Humans
Pharmacovigilance
Sleep Apnea Syndromes / chemically induced*
Valproic Acid / adverse effects*

Substances

Valproic Acid